Difference between revisions of "Borjesson PK, et al. Clin. Cancer Res. (2003) cited as Ref 552 in DOI: 10.1038/s41392-020-0110-5 (Q9815)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: title (P93): Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma, #quickstatements; #temporary_batch_1590010982689)
(‎Created claim: Page(s) (P105): 3961s-3972s, #quickstatements; #temporary_batch_1590074839150)
 
Property / Page(s)
 +
3961s-3972s
Property / Page(s): 3961s-3972s / rank
 +
Normal rank

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Borjesson PK, et al. Clin. Cancer Res. (2003) cited as Ref 552 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Borjesson PK
    0 references
    0 references
    2003
    0 references
    Clin. Cancer Res.
    0 references
    9
    0 references
    Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma (English)
    0 references
    3961s-3972s
    0 references